Arcus Biosciences prices $250 million public stock offering at $17.50 per share
Arcus Biosciences announced the pricing of a public offering of common stock. The company sold about 14.3 million shares at $17.50 each, generating $250 million in gross proceeds before expenses. Underwriters have a 30‑day option to purchase up to roughly 2.1 million additional shares, and the closing is expected on October 23, 2026, subject to customary conditions.
Why it matters
The capital raise will provide funding for Arcus’s cancer and immune‑disease programs, which are critical for a clinical‑stage biotech without product revenue. The offering caused the stock to fall 6% in pre‑market trading, reflecting dilution concerns among investors.
Key facts
- 1Arcus priced the offering at $17.50 per share. tradingview.com
- 2The offering comprised about 14.3 million shares. tradingview.com
- 3The gross proceeds are expected to be $250 million before expenses. stocktitan.net
- 4Underwriters have a 30‑day option to purchase up to approximately 2.1 million additional shares. tradingview.com
- 5Closing of the offering is expected on October 23, 2026, pending customary conditions. tradingview.com
- 6Arcus’s shares fell about 6% in pre‑market trading after the pricing announcement. gurufocus.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.